ArticleACS omega2023
Exploring the Potential of Thymoquinone-Stabilized Selenium Nanoparticles: In HEC1B Endometrial Cancer Cells Revealing Enhanced Anticancer Efficacy.
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Surface-Engineered Selenium Nanoparticles with L-Asparagine and Tartaric Acid: Therapeutic Efficacy Against Breast Cancer and Bacterial Infections.Iranian journal of medical sciences · 2026Article
- Selenium-Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Application of nanoparticles in the therapeutic management of endometrial cancer.European journal of medical research · 2026Review
- Metformin-Functionalized Selenium Nanoparticles Restore Insulin Signaling and Metabolic Homeostasis in Letrozole-Induced Polycystic Ovary Syndrome Rat Model.International journal of medical sciences · 2026Article
- Selenium Nanoparticles as Versatile Delivery Tools.Pharmaceutics · 2025Review
- Nanotechnology strategies for endometrium health: Are we on the right track?Bioactive materials · 2025Review
- Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line.Medicina (Kaunas, Lithuania) · 2025Article
- Multifaceted Applications of Zerumbone-Loaded Metal-Organic Framework-5: Anticancer, Antibacterial, Antifungal, DNA-Binding, and Free Radical Scavenging Potentials.Molecules (Basel, Switzerland) · 2025Article
- Alginate and chitosan-coated ferulic acid-loaded selenium nanoparticles: synthesis, characterization, and anticancer activity against MDA-MB-231 breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Clinical and mechanistic insights into biomedical application of Se-enriched probiotics and biogenic selenium nanoparticles.Biotechnology letters · 2025Review
- Cytotoxic effects of bee venom-loaded ZIF-8 nanoparticles on thyroid cancer cells: a promising strategy for targeted therapy.Medical oncology (Northwood, London, England) · 2024Article
- Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations.International journal of nanomedicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this research is to examine the potential anticancer properties of thymoquinone (TQ)-encapsulated selenium nanoparticles (TQ-SeNPs) in HEC1B endometrial carcinoma cells. TQ-SeNPs were synthesized, and their size, morphology, and elemental analysis were characterized. Morphological changes were examined by using scanning electron microscopy (SEM). The cytotoxicity and viability of nanothymoquinone were assessed by the XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.